37
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Influenza-Like-Illness and Clinically Diagnosed Flu: Disease Burden, Costs and Quality of Life for Patients Seeking Ambulatory Care or No Professional Care at All

      research-article
      1 , * , 2 , 3 , 1 , 4
      PLoS ONE
      Public Library of Science

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          This is one of the first studies to (1) describe the out-of-hospital burden of influenza-like-illness (ILI) and clinically diagnosed flu, also for patients not seeking professional medical care, (2) assess influential background characteristics, and (3) formally compare the burden of ILI in patients with and without a clinical diagnosis of flu. A general population sample with recent ILI experience was recruited during the 2011–2012 influenza season in Belgium. Half of the 2250 respondents sought professional medical care, reported more symptoms (especially more often fever), a longer duration of illness, more use of medication (especially antibiotics) and a higher direct medical cost than patients not seeking medical care. The disease and economic burden were similar for ambulatory ILI patients, irrespective of whether they received a clinical diagnosis of flu. On average, they experienced 5–6 symptoms over a 6-day period; required 1.6 physician visits and 86–91% took medication. An average episode amounted to €51–€53 in direct medical costs, 4 days of absence from work or school and the loss of 0.005 quality-adjusted life-years. Underlying illness led to greater costs and lower quality-of-life. The costs of ILI patients with clinically diagnosed flu tended to increase, while those of ILI patients without clinically diagnosed flu tended to decrease with age. Recently vaccinated persons experienced lower costs and a higher quality-of-life, but this was only the case for patients not seeking professional medical care. This information can be used directly to evaluate the implementation of cost-effective prevention and control measures for influenza. In particular to inform the evaluation of more widespread seasonal influenza vaccination, including in children, which is currently considered by many countries.

          Related collections

          Most cited references17

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          Self-medication with Antimicrobial Drugs in Europe

          Antimicrobial drug resistance is a rapidly increasing global problem ( 1 , 2 ), and prevalence varying widely among countries ( 3 ). Prevalence of resistance is positively correlated with prescribed outpatient drug use on a national level ( 4 , 5 ). However, actual consumption of drugs may also include self-medication, i.e., using drugs obtained without prescription. Other sources of self-medication may include leftover drugs from treatment courses prescribed earlier or drugs obtained from relatives or friends. Use without medical guidance is inappropriate because using insufficient dosages or incorrect or unnecessary drugs increases the risk of the selection of resistant bacteria ( 6 ) and the spread of antimicrobial drug resistance ( 7 ). To date, the information on self-medication with antimicrobial drugs in the industrialized world is limited. In the United States, several studies indicate considerable use of leftovers ( 8 – 10 ), drugs obtained from a family member, a pharmacy, or a source outside the country ( 11 , 12 ). For example, in an Hispanic neighborhood of New York City, antimicrobial drugs are available without a prescription ( 13 ). In Europe, studies describing self-medication and storage of antimicrobial drugs in Spain ( 14 , 15 ), Greece ( 16 , 17 ), Russia ( 18 ), and Malta ( 19 ) also suggest considerable use of the drugs without consulting a physician. However, these studies were small or used selected samples and were not carried out in northern and western Europe. Moreover, because of the different research methods used, no meaningful comparison between countries was possible. In addition, little information exists on factors that puts person at-risk for self-medication. This survey was designed to fill that gap for 19 European countries: Austria, the Netherlands, Sweden, United Kingdom, Ireland, Denmark, Italy, Malta, Luxembourg, Belgium, Spain, Israel, Romania, Czech Republic, Slovakia, Lithuania, Slovenia, Croatia, and Poland. The aim of this study was to estimate and compare the prevalence of actual self-medication and at-risk for self-medication with antimicrobial drugs in participating countries. The demographic characteristics associated with such use, the types of drugs used, the sources of self-medication, the symptoms for which the drugs were reportedly used, and duration of use were also examined. Methods Countries participating in the study were recruited from 2 networks of surveillance systems: European Surveillance of Antimicrobial Consumption ( 20 ) and European Antimicrobial Resistance Surveillance System ( 21 ). A multistage sampling design was used for sample selection in each participating country. Within each country, a region with average prescribed antimicrobial drug consumption was chosen. In those countries where this information was not available (Poland, Czech Republic, Lithuania, Croatia, and Romania), a region was selected that was representative of the country's population in terms of age and sex. In each region, a city (75,000–750,000 inhabitants) and a rural area (5,000–10,000) were selected. By using population registries, including lists of persons in the identified cities and rural areas, persons >18 years of age were selected by simple random sampling (computer-generated random numbers). To calculate the sample size, we needed the standard deviation of the unknown prevalence. As the standard deviation was a function of this unknown prevalence, we took the maximal possible value of the standard deviation ( 22 ). To obtain a precision of 0.05, the sample size needed was 400 persons per country. To adjust for possible nonresponse, we selected larger samples; sample sizes in the countries were 1,000–3,000 persons, equally distributed in urban and rural areas. Self-administered questionnaires were mailed between March and July 2003, and reminders with a new questionnaire attached were sent 2–4 weeks later. We developed an English questionnaire specifically for this survey, translated it into national languages, and back-translated it to ensure consistency.1 The questionnaire was pilot-tested in each country. It could be completed either anonymously or with identifiable details to allow a follow-up study. Questions asked about the respondent's use of antimicrobial drugs during the past 12 months, how they were obtained, how they were stored at home, and whether the respondent would consider using drugs without consulting a physician. Details of the drugs used (name of the medicine, symptom or disease coded with International Classification of Primary Care codes [23], and duration of use) and demographic characteristics of the respondents were included. Antibacterial drugs for systemic use (Anatomical Therapeutic Chemical class J01) ( 24 ) were included in the analyses. Medicines erroneously reported as antimicrobial drugs were excluded from the analyses. Ethics or data committee approval for the survey was required in Sweden, Denmark, Belgium, United Kingdom, Ireland, Malta, Czech Republic, Slovenia, Croatia, Romania, and Lithuania and was obtained from the local ethics or data committees of these countries. Respondents were classified as self-medicating if they reported that they had taken any antimicrobial drugs in the previous 12 months without a prescription from a physician, dentist, or nurse and as prescribed users if antimicrobial drugs had been prescribed. (Physician respondents who reported using nonprescribed drugs were not classified as self-medicating.) Those classified as at-risk for self-medication included those who indicated the intention to self-medicate or store drugs at home. Intended self-medication was defined as answering "yes" or "maybe" to the question, "In general, would you use antimicrobial drugs for yourself without contacting a doctor/nurse/hospital?" Two estimates were used to assess storage of drugs: a maximum estimate, including all respondents who stored antimicrobial drugs, and a conservative estimate that excluded those respondents who stored antimicrobial drugs and had taken the same drugs for a prescribed course in the previous 12 months. Statistical Analyses Descriptive statistics were used to estimate the prevalence rates per 1,000 respondents and 95% confidence intervals (CI) for actual self-medication and prescribed use in the previous 12 months and for at-risk self-medication in each country. To assess possible bias from low response rates, we also estimated adjusted prevalence rates. We applied the continuum of the resistance model ( 25 ), based on the assumption that late respondents most resemble nonrespondents. Late respondents in our study were those who replied after the reminder. The adjusted prevalence is considered similar to the observed prevalence when it falls in the 95% CI of the observed prevalence. The effects of individual characteristics and country on antimicrobial drug self-medication were studied with logistic regression analyses by using 3 outcome variables: actual self-medication in the previous 12 months, storage of antimicrobial drugs, and intended self-medication. Countries were grouped together in 3 European regions: northern and western (Sweden, Denmark, the Netherlands, Austria, Belgium, Luxemburg, United Kingdom, and Ireland), southern (Malta, Italy, Israel, and Spain), and eastern (Czech Republic, Slovenia, Croatia, Poland, Slovakia, Romania, and Lithuania). This grouping was based on patterns of prescribed use of antimicrobial drugs ( 4 ), geographic location ( 26 ), similarities in healthcare systems, and socioeconomic development. The former socialist countries are referred to as eastern countries. We tested possible interactions between the factors found to be significant and set the significance at p 40% and 40% Northern and western The Netherlands (Twente) 1 (0.2–4) 152 (134–170) 85 (71–101) 10 (6–17) 36 (28–46) Sweden (Vastmanland) 4 (0.9–12) 135 (109–161) 118 (94–143) 14 (7–26) 43 (29–60) Denmark (Funen, Aarhus, Copenhagen‡) 7 (4–12) 172 (154–189) 132 (116–147) 42 (33–52) 84 (72–97) Luxemburg (whole country) 9 (3–19) 288 (252–324) 83 (62–107) 90 (69–114) 132 (106–158) Belgium (East Flanders, Flemish Brabant) 9 (5–15) 222 (201–242) 80 (67–95) 71 (59–84) 123 (107–138) Southern Malta (whole country) 56 (38–79) 422 (380–465) 228 (192–264) 156 (125–186) 269 (232–306) Eastern Czech Republic (Hradec Krlov) 7 (3–13) 253 (228–279) 179 (156–201) 45 (33–58) 64 (51–80) Slovakia (Middle Slovakia region) 42 (27–63) 569 (527–612) 324 (284–365) 192 (159–225) 302 (263–340) Romania (Dolj) 198 (160–235) 307 (263–351) 431 (383–478) 200 (162–238) 321 (277–365) Countries with response rate 750,000, both self-medication and prescribed use of antimicrobial drugs were not significantly different between the sample of Copenhagen and sample of the other 2 Danish counties (χ2 tests).
§The rates for these countries should be interpreted as first rough estimates. We compared our estimates of antimicrobial drug self-medication with data available from the European Union's Eurobarometer survey in October 2002 ( 27 ). We calculated the prevalence of drug use from "leftovers" and drugs "directly from the pharmacy" by using the Eurobarometer data and compared these figures with the same estimates in our study. The estimates were similar with overlapping 95% CIs (data not shown) for countries with both high and low response rates. Our figures differed regarding Spain, for which we found a higher prevalence of self-medication than did the Eurobarometer. Three other studies ( 4 , 15 , 28 ) indicated an even higher prevalence of self-medication in Spain than in our estimate. Types of Antimicrobial Drugs Used for Self-medication and Duration of Use Antimicrobial drugs from all classes were used for self-medication in countries with response rates both >40% and 40%, southern and eastern countries used significantly more broad-spectrum penicillin for self-medication than northern and western countries (χ2, p 40%, a throat symptom was also the most common, followed by symptoms of the teeth or gums (Figure 1). Symptoms such as inflammation, skin infection, or diarrhea were reported only in countries with lower response rates. Self-medication for pyelonephritis or pyelitis was reported only in Lithuania; diarrhea was reported in Lithuania (10 patients; 9 used chloramphenicol), Austria (1 patient), and United Kingdom (1 patient). Figure 1 Prevalence of actual self-medication by symptoms or diseases classified by International Classification of Primary Care codes (rates pre 1,000 respondents and 95% confidence iinterval). *Symptoms or diseases with rates 40%, sore throat and urinary tract infection were also the most common symptoms (Figure 2). Figure 2 Prevalence of intended self-medication per predefined symptom (rates per 1,000 respondents and 95% confidence interval). In eastern countries, the major source of self-medication was the pharmacy without prescription (309 courses, 68%), followed by leftover medications (120 courses, 26%). By contrast, in southern, northern, and western countries use of leftover medication was more prevalent (46 courses [51%] in southern countries and 35 courses [44%] in northern and western countries), followed by medications obtained directly from the pharmacy (41 courses [46%] in southern countries and 15 courses [19%] in northern and western countries). Among other sources of self-medication were drugs obtained from relatives or friends (52 courses, 8%, in all countries), drugs that were stored after being obtained abroad (10 courses, 2%, in all countries), and drugs obtained over the Internet (3 courses, all in Lithuania). Effects of Individual Characteristics The effects of demographic characteristics and chronic disease on actual self-medication, intended self-medication, and storage of antimicrobial drugs are shown in Table 3. Sex and location (urban or rural) had no significant relevance in any of the 3 models. Respondents from southern and eastern countries were more likely to self-medicate (adjusted odds ratio [OR] 6.8, 95% CI 4.8–9.7, and 7.5, 5.7–10.0, respectively) than respondents from northern and western countries. Younger age, higher educational level, and presence of a chronic disease were all significantly associated with self-medication. Similar results were obtained for the relationship between demographic characteristics and storage of antimicrobial drugs, by using the conservative estimate of storage. Younger age, higher educational level, and presence of a chronic disease were also significant predictors of intended self-medication. Presence of a chronic disease increased the risk of intended self-medication, but this effect diminished with increasing age. We repeated all analyses including only those countries that had response rates >40% and obtained similar results. We also repeated these analyses separately for early and late respondents and obtained similar results.3 Table 3 Effects of individual characteristics on actual and at-risk antimicrobial drug self-medication* Characteristics Adjusted odds ratio (95% confidence interval) Actual self-medication Storage (conservative estimate) Intended self-medication Age 0.985 (0.979–0.992) 0.977 (0.973–0.982) 0.984 (0.980–0.987) Region in Europe† Northern and western 1 (reference) 1 1 Southern 6.776 (4.752–9.662) 5.101 (4.240–6.137) 2.233 (1.909–2.613) Eastern 7.529 (5.676–9.985) 3.311 (2.868–3.822) 2.851 (2.577–3.154) Education level Low‡ 1 (reference) 1 1 High 1.357 (1.095–1.680) 1.690 (1.470–1.943) 1.233 (1.116–1.361) Chronic disease§ No 1 (reference) 1 1 Any 1.888 (1.497–2.383) 1.225 (1.038–1.446) 2.320(1.594–3.378) Age × any chronic disease 0.989 (0.982–0.996) Exponential (constant) 0.012 0.083 0.219 *At-risk self-medication included intended self-medication or storage of drugs at home.
†Northern and western includes Sweden, Denmark, the Netherlands, Austria, Belgium, Luxemburg, United Kingdom, Ireland; southern includes Israel, Malta, Italy, and Spain; eastern includes Czech Republic, Slovenia, Croatia, Poland, Slovakia, Romania, and Lithuania.
‡Low education level was defined as incomplete primary education, completed primary education, and lower vocational or general education.
§Including any of the following diseases: asthma, chronic bronchitis, emphysema, HIV infection, cystic fibrosis, diabetes, endocarditis, tuberculosis, prostatitis, chronic urinary tract infection, chronic osteomyelitis, peptic ulcer disease, chronic pyelonephritis, or cancer. Relation between Intended Self-medication, Storage, and Actual Self-medication Intended self-medication and storage are both predictors of actual self-medication. A significant relationship was found between intended self-medication and storage. Intended self-medication was a strong predictor for actual self-medication for both respondents who stored drugs (OR 20.9, 95% CI 15.5–28.2) and those who did not (OR 17.8, 95% CI 14.0–22.7). However, for those who did not intend to self-medicate, storage also predicted higher actual self-medication (OR 3.5, 95% CI 2.2–5.6). When the analyses were repeated, including only those countries that had response rates >40%, similar results were obtained.3 Conclusions Self-medication with antimicrobial drugs occurred in all countries that participated in this survey. We included the data from both countries that had high and low response rates. In most of the countries with low response rates (except Spain), no other information is available about self-medication, an often overlooked issue. The second reason for including these countries was that low response was not a problem of this study only, but a general problem of surveys in these countries ( 29 , 30 ). This finding implies that if we want to include information about these countries, the results may be biased. In addition, debate is growing that low response is less problematic in affecting survey estimates than previously assumed ( 31 ). Nevertheless, the prevalence rates of self-medication in countries with low response rates should be considered as a rough estimate and interpreted as an indication that the problem exists. Antimicrobial drug self-medication prevalence varies widely among different European regions, with the highest rates in eastern and southern countries, and the lowest in northern and western. Besides actual self-medication, intended self-medication is clearly relevant: it is a strong predictor of actual self-medication. Intended self-medication has a much higher prevalence than actual self-medication, indicating that the population at-risk is much larger than those who have actually self-medicated in the previous 12 months. Another risk factor for actual self-medication is the availability of drugs at home; opportunity encourages use. Our findings contribute to the growing evidence that estimates of antimicrobial drug use that are based on prescription data only are likely to underestimate actual consumption in both Europe and the United States ( 11 , 32 ). Our European estimates are low in comparison with those from a recent study in the US Hispanic community that showed that ≈20% of the respondents acknowledged getting drugs without a prescription in the United States ( 32 ). The only comparable high rates were found in Spain, Romania, and Lithuania, where they ranged from 9% to 18%. However, these figures should be compared with caution because our estimates refer to acquiring drugs without prescription in the last 12 months and the United States study refers to ever acquiring them. We found that many persons used antimicrobial drug leftovers from previous prescriptions, as was the case in reports from the United States ( 8 – 10 , 12 ). Drugs could be left over because extra tablets were dispensed (in many countries pharmacies dispense drugs per package, not exact number of tablets) or because of patient noncompliance. Noncompliance may result in 2 inappropriate courses if the patient does not take the amount of medication prescribed and self-medicates later. Earlier findings indicated lower compliance in Italy and Spain than in Belgium, France, and the United Kingdom ( 33 ). In Italy, 41% of the interviewees who had taken drugs in the previous 12 months saved part of the course for future use, whereas only 4% of British interviewees reported this behavior ( 33 ). In general, respondents' self-diagnosed disorders were self-limiting and antimicrobial drugs would not have been indicated. In contrast to studies in developing countries, this study identified few cases of self-medication for sexually transmitted diseases ( 34 , 35 ). Only 2 respondents in Lithuania reported self-medication for "gynecological infection" that might have been a sexually transmitted infection. In this survey, persons who were more prone to self-medicate with antimicrobial drugs were younger persons, more educated, and had chronic diseases. This finding corresponds to those of studies conducted in the United States and Greece, which also found that higher educational status is associated with misuse of drugs ( 8 , 17 ). This relationship cannot be directly attributed to educational status. The interpretation of symptoms is also relevant. Previously, a study in the United States showed that persons with a higher education level tended to believe that antimicrobial drugs were less effective for upper respiratory infections with clear discharge but more effective with discolored discharge ( 36 ). Antimicrobial drug self-medication is a cause for concern because it may contribute to the spread of antimicrobial drug resistance. Self-treatment with a drug that is ineffective against the causative organism or with an inappropriate dosage may increase the risk of selection of resistant organisms that are difficult to eradicate. These resistant organisms may then be transferred into the community. Our findings illustrate that adverse effects are aggravated by self-medication when unnecessary drugs, such as chloramphenicol, tetracycline, and aminoglycosides, are taken. Other problems related to self-medication include drug interactions, masked diagnoses, and superinfection. Our results are comparable to those of other studies such as the Eurobarometer study ( 14 , 19 , 27 ). A study on antimicrobial drug storage among Spanish households showed that 42% of Spanish households had drugs at home, including those currently used ( 14 ). This finding is comparable to the prevalence of drugs stored (50%) in our study. In Malta, a higher prevalence (19%) of self-medication was found ( 19 ) than in our study, perhaps because the study included self-medication in the previous 2 years, while our study included the previous 12 months. Furthermore, the pattern of the prescribed use of drugs in different regions of Europe in our study is similar to that found in the study by Goossens et al., which was based on information from national databases ( 4 ). A strength of our study is that we used the same methods and comparable samples in all countries, which facilitated an overview of the European situation. The low response rate in some countries is a limitation of our study, however. Although we calculated the prevalence rates adjusted for nonresponse, they are based on the assumption that respondents who replied after the reminder most resemble nonrespondents. As with all self-reported data, results of this survey have the potential for recall bias, underreporting, or overreporting. We attached the list of the most commonly used antimicrobial drugs in each country to the questionnaires to reduce recall problems. To discourage underreporting of self-medication, the questions about drug use were formulated in a neutral way in which the source of the drug could be chosen from 6 predefined sources or "other source." Substantial variation in the prevalence rates of antimicrobial drug self-medication among the European regions suggests that cultural ( 37 ) and socioeconomic factors play a role, as do disparities in health care systems such as reimbursement policies, access to health care, and drug dispensing policies. Another factor is the acquisition of antimicrobial drugs from pharmacies without prescription, which occurred most frequently in eastern European countries. Although over-the-counter sale of antimicrobial drugs is illegal in all participating countries, there is clearly a need to enforce the law in some countries. Antimicrobial drug self-medication is a cause for concern in Europe. Even the lowest prevalence, 1 person per 1,000 respondents, implies that 10,000 persons in a population of 10,000,000 are self-medicating annually. Our study indicates a high prevalence of self-medication in countries that reported high resistance levels (southern and eastern countries). Even in the countries with low actual self-medication, substantial intended self-medication and drug storage occurs. Efforts to reduce inappropriate use of antimicrobial drugs should include the issue of self-medication and should involve prescribers, pharmacists, and the general public. The number of tablets dispensed in pharmacies should be limited, and patients should be instructed to discard their leftover drugs. Large-scale public campaigns, such as those recently launched in the United States, Canada, Belgium, and Australia ( 38 ), should include detailed instructions and emphasize the potential risks of using antimicrobial drugs without medical guidance.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found
            Is Open Access

            Amoxicillin for acute lower-respiratory-tract infection in primary care when pneumonia is not suspected: a 12-country, randomised, placebo-controlled trial.

            Lower-respiratory-tract infection is one of the most common acute illnesses managed in primary care. Few placebo-controlled studies of antibiotics have been done, and overall effectiveness (particularly in subgroups such as older people) is debated. We aimed to compare the benefits and harms of amoxicillin for acute lower-respiratory-tract infection with those of placebo both overall and in patients aged 60 years or older. Patients older than 18 years with acute lower-respiratory-tract infections (cough of ≤28 days' duration) in whom pneumonia was not suspected were randomly assigned (1:1) to either amoxicillin (1 g three times daily for 7 days) or placebo by computer-generated random numbers. Our primary outcome was duration of symptoms rated "moderately bad" or worse. Secondary outcomes were symptom severity in days 2-4 and new or worsening symptoms. Investigators and patients were masked to treatment allocation. This trial is registered with EudraCT (2007-001586-15), UKCRN Portfolio (ID 4175), ISRCTN (52261229), and FWO (G.0274.08N). 1038 patients were assigned to the amoxicillin group and 1023 to the placebo group. Neither duration of symptoms rated "moderately bad" or worse (hazard ratio 1.06, 95% CI 0.96-1.18; p=0.229) nor mean symptom severity (1.69 with placebo vs 1.62 with amoxicillin; difference -0.07 [95% CI -0.15 to 0.007]; p=0.074) differed significantly between groups. New or worsening symptoms were significantly less common in the amoxicillin group than in the placebo group (162 [15.9%] of 1021 patients vs 194 [19.3%] of 1006; p=0.043; number needed to treat 30). Cases of nausea, rash, or diarrhoea were significantly more common in the amoxicillin group than in the placebo group (number needed to harm 21, 95% CI 11-174; p=0.025), and one case of anaphylaxis was noted with amoxicillin. Two patients in the placebo group and one in the amoxicillin group needed to be admitted to hospital; no study-related deaths were noted. We noted no evidence of selective benefit in patients aged 60 years or older (n=595). When pneumonia is not suspected clinically, amoxicillin provides little benefit for acute lower-respiratory-tract infection in primary care both overall and in patients aged 60 years or more, and causes slight harms. European Commission Framework Programme 6, UK National Institute for Health Research, Barcelona Ciberde Enfermedades Respiratorias, and Research Foundation Flanders. Copyright © 2013 Elsevier Ltd. All rights reserved.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Clinical manifestations and socio-economic impact of influenza among healthy children in the community.

              To evaluate the total burden of influenza among healthy children in the community in order to analyse the cost of influenza in paediatric age. This prospective study involved a total community population of 21,986 children, 6988 of whom experienced an influenza-like illness (ILI) between 1 November 2008 and 30 April 2009. An electronic chart was completed, a nasopharyngeal swab was obtained, and information was recorded concerning the clinical outcomes and household impact of the ILI episodes. Influenza A and B viruses were detected in all the swabs by means of polymerase chain reaction, and costs of the disease were calculated. Influenza viruses were detected in 2143 cases (30.7%), an incidence of 96.4 per 1000 children. Influenza A and B viruses were found in respectively 1751 (81.7%) and 392 cases (18.3%). The mean cost of influenza was no less than €130, 32% higher than the cost of influenza-negative ILIs (p 5 years (p < 0.05). The differences were mainly related to the indirect costs of the parents' lost working days. The findings of this study confirm that influenza among healthy children is important because of its frequency and its indirect consequences on the households of infected children, and support the use of influenza vaccination in healthy children aged between 6 months and 5 years. Copyright © 2011 The British Infection Association. Published by Elsevier Ltd. All rights reserved.
                Bookmark

                Author and article information

                Contributors
                Role: Editor
                Journal
                PLoS One
                PLoS ONE
                plos
                plosone
                PLoS ONE
                Public Library of Science (San Francisco, USA )
                1932-6203
                2014
                17 July 2014
                : 9
                : 7
                : e102634
                Affiliations
                [1 ]Centre for Health Economics Research & Modelling Infectious Diseases (CHERMID), Vaccine & Infectious Disease Institute (VAXINFECTIO) WHO collaborating Centre, Faculty of Medicine & Health Sciences, University of Antwerp, Antwerp, Belgium
                [2 ]Centre for General Practice, Primary and Interdisciplinary Care (ELIZA), Faculty of Medicine & Health Sciences, University of Antwerp, Antwerp, Belgium
                [3 ]Laboratory of Medical Microbiology, Vaccine & Infectious Disease Institute (VAXINFECTIO) WHO collaborating Centre, Faculty of Medicine & Health Sciences, University of Antwerp, Antwerp, Belgium
                [4 ]School of Public Health and Community Medicine, Sydney, Australia
                Fondazione Bruno Kessler, Italy
                Author notes

                Competing Interests: The authors have declared that no competing interests exist.

                Conceived and designed the experiments: JB PB. Performed the experiments: JB SC PB. Analyzed the data: JB. Contributed reagents/materials/analysis tools: JB SC PB. Wrote the paper: JB SC PB.

                Article
                PONE-D-13-52404
                10.1371/journal.pone.0102634
                4102549
                25032688
                61ef3eae-170e-4d33-a209-e8f56789a849
                Copyright @ 2014

                This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

                History
                : 28 January 2014
                : 23 June 2014
                Page count
                Pages: 11
                Funding
                This study was funded by the Belgian Health Care Knowledge Centre. JB is supported by a postdoctoral grant from the Research Foundation – Flanders (FWO). GRACE is funded via European Commission Framework Programme 6 and Research Foundation – Flanders (FWO G.0274.08N). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
                Categories
                Research Article
                Medicine and Health Sciences
                Health Care
                Health Economics
                Infectious Diseases
                Viral Diseases
                Influenza
                Pathology and Laboratory Medicine
                Pharmacology
                Drug Information
                Pulmonology
                Respiratory Infections
                Physical Sciences
                Mathematics
                Statistics (Mathematics)
                Biostatistics
                Social Sciences
                Economics
                Economic Analysis
                Cost-Effectiveness Analysis

                Uncategorized
                Uncategorized

                Comments

                Comment on this article